

08/26/99 JCS55 U.S. PTO

Customer No. 000959

Case Docket No. BBI-102CP

A  
JCS55 U.S. PTO  
09/30/98  
08/26/99

THE ASSISTANT COMMISSIONER FOR PATENTS  
Box Patent Application  
Washington, D.C. 20231

"Express Mail" Mailing Label Number EL 178 765 888 US  
Date of Deposit August 26, 1999  
I hereby certify that this transmittal letter and the papers referred to as being enclosed therein are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.  
Nelson Barros  
Signature  
Nelson Barros  
Please Print Name of Person Signing

Sir:

Transmitted herewith for filing is the patent application of

Inventor(s): Heinz Schaller, Ulrike Protzer, and Michael Nassal

For: METHODS AND COMPOSITIONS FOR EXPRESSING HETEROLOGOUS GENES IN HEPATOCYTES USING HEPADNAVIRAL VECTORS

Enclosed are:

- ☒ This is a request for filing an application under 37 CFR 1.53(b), which application is a utility conversion of prior Provisional Application Serial No. 60/098,173, filed August 26, 1998 and entitled "Methods and Compositions for Expressing Heterologous Genes in Hepatocytes Using Hepadnaviral Vectors".
- ☒ 30 pages of specification, 5 pages of claims, 1 page of abstract.
- ☒ 7 sheets of drawings (Figures 1-7).
- ☒ A Declaration, Petition and Power of Attorney (6 pp., unexecuted).
- ☐ An assignment of the invention to . A recordation form cover sheet (Form PTO 1595) is also enclosed.
- ☐ A verified statement to establish small entity status under 37 C.F.R. 1.9 and 37 C.F.R. 1.27.
- ☐ Other

The filing fee has been calculated as shown below:

(Col. 1)		(Col. 2)	SMALL ENTITY		OR	OTHER THAN SMALL ENTITY	
FOR:	NO. FILED	NO. EXTRA	RATE	FEE		RATE	FEE
BASIC FEE	////////////////////		////////	\$	OR	////////	\$ 760
TOTAL CLAIMS	40 - 20	= 20	x 9=	\$	OR	x 18=	\$ 360
INDEP. CLAIMS	5 - 3	= 2	x 39	\$	OR	x 78	\$ 156
<input type="checkbox"/> MULTIPLE DEPENDENT CLAIMS PRESENTED			+130	\$	OR	+260	\$
			TOTAL	0	OR	TOTAL	\$1276.00

\* If the difference in Col. 2 is less than zero, enter "0" in Col. 2.

☐ Please charge my Deposit Account No. in the amount of \$.  
A duplicate copy of this sheet is enclosed.

☒ The filing fees are not being paid at this time.

☐ The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. .  
A duplicate copy of this sheet is enclosed.

- ☐ Any additional filing fees required under 37 C.F.R. 1.16.
- ☐ Any patent application processing fees under 37 C.F.R. 1.17.

- ☐ The Commissioner is hereby authorized to charge payment of the following fees during the pendency of this application or credit any overpayment to Deposit Account No.  
A duplicate copy of this sheet is enclosed.
- ☐ Any patent application processing fees under 37 C.F.R. 1.17.
- ☐ The issue fee set in 37 C.F.R. 1.18 at or before mailing of the Notice of Allowance, pursuant to 37 C.F.R. 1.311(b).
- ☐ Any filing fees under 37 C.F.R. 1.16 for presentation of extra claims.
- ☐ A check in the amount of \$ \_\_\_\_\_ to cover the recording of assignment documents is also enclosed.
- ☒ Address all future communications (May only be completed by applicant, or attorney or agent of record) to Elizabeth A. Hanley, Esq. at **Customer Number: 000959** whose address is:

Lahive & Cockfield, LLP  
28 State Street  
Boston, Massachusetts 02109

Date: August 26, 1999

LAHIVE & COCKFIELD, LLP  
Attorneys at Law

By 

Amy E. Mandragouras, Reg. No. 36,207 for  
Elizabeth A. Hanley, Reg. No. 33,505  
28 State Street  
Boston, MA 02109  
(617) 227-7400  
Telecopier (617) 742-4214

## Methods and Compositions for Expressing Heterologous Genes in Hepatocytes Using Hepadnaviral Vectors

### Related Applications

- 5 This application claims priority to U.S. Provisional Application No. 60/098,173, filed on August 26, 1998, incorporated herein in its entirety by this reference.

### Background of the Invention

- Chronic hepatitis B is one of the most common and most severe viral infections known with the number of virus carriers estimated to exceed 350 million (Who (1996) *WHO Communicable*, 1:1-26). These individuals are at high risk of developing liver cirrhosis and, eventually, primary liver cell carcinoma (Lau *et al.*, (1993) *Lancet* 342:1335-1340). While a vaccine is available, currently used systemic treatment of chronic infection with high doses of interferon alpha (IFN $\alpha$ ) leads to HBeAg / anti-HBe seroconversion in about one third of treated patients, and to virus elimination in only 10-25% of treated patients (Hoofnagle *et al.* (1997) *J. Viral Hepat.* 1:41-50; Lau *et al.* (1997) *Gastroenterology* 113:1660-1667). Furthermore, the currently used treatment regimen is costly and often has side effects.

- The causative agent of hepatitis B disease is the hepatitis B virus (HBV), a member of the hepadnaviruses family. These small, DNA-containing viruses replicate through reverse transcription, like retroviruses, but do not integrate into the host cell genome for replication. One characteristic property of the hepadnaviruses is their high species and tissue-specificity. HBV replicates only in the liver of humans and higher primates and infects *in vitro* only primary hepatocytes of these hosts.

- To date, most gene transfer clinical trials have relied on recombinant retroviral or adenoviral vectors for gene transfer, although both retroviral or adenoviral technologies have limitations. For example, with adenoviral vectors, the high multiplicity of infection may result in cytotoxicity in the target cells (Kay *et al.*, (1993) *Cell Biochem*, 17E, 207), and the host immune response against adenoviral late gene products, e.g. penton protein, cause an inflammation response and the destruction of the infected tissue which received the vectors (Yang *et al.*, (1994) *Proc. Natl. Acad. Sci.* 92, 4407-4411). With retroviral vectors, the murine leukemia virus (MLV) is most widely used. However, it is difficult to produce a virus at a reasonable titre for targeting a specific cell type or tissue by direct *in vivo* delivery with MLV-based vectors (Kasahara *et al.*, (1994) *Science*, 266, 1373-1376), and MLV-vectors, when packaged in murine packaging lines, cannot deliver a gene of interest to non-dividing cells such as hepatocytes. A further disadvantage of both retroviral or adenoviral technologies results from their ability to

infect a broad range of cell types. Therefore, these gene therapy vectors are not ideal for specific delivery of genes to hepatocytes.

Hepadnaviridae are small enveloped DNA-viruses that employ for genome replication a reverse transcription pathway without requiring integration into the host genome. As exemplified by their type-member, the human hepatitis B virus (HBV) which infects only hepatocytes of humans and hominoid primates, hepatitis B viruses are highly species- and tissue-specific, targeted to the liver, and capable of infecting non-dividing hepatocytes. Because of these properties, they have been considered as attractive candidates for therapeutic, liver-directed gene transfer.

Early studies in the duck hepatitis B virus (DHBV) animal model had suggested that this was principally possible, although an effective gene delivery system remains to be developed. DHBV genomes containing short deletions, or small insertions of non-coding DNA, could be complemented in trans to allow formation of infectious, defective DHBV particles (Horwich, A.L. et al. (1990) *J. Virol.* 64:542-550). However, these data also revealed severe constraints with respect to the insert size. More recent attempts to produce HBV recombinants were in keeping with these observations: even insertion of a small marker gene (HIV-1 tat, 276 bp) markedly reduced the yield of enveloped virus particles (Chaisomchit, S. et al. (1997) *Gene Ther.* 4:1330-1340), while insertion into various parts of the viral genome of an 800 bp cassette containing the neomycin resistance gene was found to require compensation by comparably sized deletions (Chiang, P.W. (1992) Thesis, University of Heidelberg). In either study, expression of the transgene could be demonstrated only in transient transfection experiments, but not via an infectious recombinant virus particle. Hence, there is at present no experimental evidence demonstrating the capability of hepadnaviruses to function as gene-transfer vectors.

In view of the foregoing, methods and compositions for delivering a heterologous gene (*e.g.*, a therapeutic gene) to hepatocytes via infection with a recombinant hepadnaviral particle such that expression of the heterologous gene is achieved in the hepatocytes are still needed.

### **Summary of the Invention**

The invention provides methods and compositions for efficient, hepatocyte-specific delivery and expression of heterologous genes, both *in-vitro* and *in-vivo*, using hepadnaviral vectors.

Hepatitis B viruses are hepatotropic DNA viruses that replicate extrachromosomally. The current invention is based, at least in part, on experiments using the duck hepatitis B virus (DHBV) model, that demonstrate that recombinant hepadnaviruses are suitable for liver-directed gene transfer. Green fluorescent protein as

an intracellular marker, and a type 1 Interferon as a secretory protein with therapeutic potential, were expressed in a hepatocyte-specific, dose-dependent fashion upon DHBV gene transfer. Cells with pre-existing DHBV infection could be superinfected with recombinant virus, and Interferon expression efficiently suppressed wild-type virus replication. Similar HBV vectors were prepared and also were effective for delivering heterologous genes to hepatocytes. Thus, HBV-based viral vectors offer a novel approach to the treatment of liver disorders including chronic viral infections.

In one aspect, the invention pertains to a method for expressing a heterologous gene in hepatocytes. The method involves:

providing replication defective hepadnavirus particles at a titre level competent to infect hepatocytes, wherein a region of the preS/S-gene of the hepadnavirus genome has been replaced with the heterologous gene such that expression of the heterologous gene is regulated by regulatory sequences of the preS/S-gene; and

infecting hepatocytes with the hepadnavirus such that the heterologous gene is delivered into the hepatocytes and expressed in the hepatocytes.

Preferably, the replication defective hepadnavirus particles are human hepatitis B virus particles.

In one embodiment, the heterologous gene is inserted into a region of the S-gene such that nucleotides encoding at least one amino acid of the S protein are fused in-frame to the 5' end of the heterologous gene. In another embodiment, the heterologous gene replaces a region of the S-gene at a site equivalent to the KpnI site at position 1290 of duck hepadnavirus. In still another embodiment, the heterologous gene replaces a region of the S-gene at a site equivalent to the KpnI site at position 1290 of duck hepadnavirus, and the heterologous gene is inserted such that nucleotides encoding at least one amino acid of the S protein are fused in-frame to the 5' end of the heterologous gene. In yet another embodiment, the heterologous gene replaces a region of the S-gene, and the heterologous gene is inserted such that nucleotides encoding at least one amino acid of the S protein are fused in-frame to the 5' end of the heterologous gene. In yet another embodiment, the heterologous gene replaces the S-gene. In still another embodiment, the heterologous gene replaces the S-gene and at least part of the preS region.

Preferred heterologous genes for expression in hepatocytes are genes encoding modulating agents (i.e., agents that modulate a viral infection of the hepatocytes or other disorder of the hepatocytes). Preferred modulating agents are cytokines. A particularly preferred cytokine is IFN $\alpha$  (Type I IFN).

Another aspect of the invention pertains to a method of treating a subject with a hepatic disorder. The method involves:

providing replication defective hepadnavirus particles at a titre level competent to infect hepatocytes of the subject with the hepatic disorder, wherein a region of the S-gene of the hepadnavirus genome has been replaced with a therapeutic gene such that expression of the therapeutic gene is regulated by regulatory sequences of the preS/S-gene; and

infecting hepatocytes of the subject with the hepadnavirus particles such that the therapeutic gene is delivered into the hepatocytes and expressed in the hepatocytes at a level sufficient to treat the hepatic disorder.

Preferred hepatic disorders to be treated by the method include hepatitis B, hepatitis C, hepatocellular carcinoma, cirrhosis, steatosis, hemochromatosis, and inherited liver disorders.

Preferred therapeutic genes include genes encoding modulating agents, such as cytokines. Preferred cytokines include IFN $\alpha$ , IFN $\beta$ , IFN $\gamma$ , IL-18 and TNF $\alpha$ .

In one embodiment, the hepadnavirus particle is directly administered to the subject. In another embodiment, the hepadnavirus construct and a helper virus construct are cultured *in vitro* and the infectious particles produced from the culture are administered to the subject. In another embodiment, recombinant hepadnavirus particles are produced by a helper cell line, and are administered to the subject.

The invention also provides a method of treating a subject with a hepatitis infection. The method involves:

providing replication defective hepadnavirus particles at a titre level competent to infect hepatocytes of the subject with hepatitis, wherein a region of the S-gene of the hepadnavirus genome has been replaced with a gene encoding a cytokine such that expression of the gene encoding a cytokine is regulated by regulatory sequences of the preS/S-gene; and

infecting hepatocytes of the subject with the hepadnavirus such that the gene encoding a cytokine is delivered to the hepatocytes and expressed in the hepatocytes at a level sufficient to treat the hepatitis.

Preferably, the cytokine is IFN $\alpha$ . Alternatively, the cytokine can be, for example, TNF $\alpha$ , IFN $\beta$ , IL-18 or IFN $\gamma$ .

In a particularly preferred embodiment, the hepatitis infection is hepatitis B and the cytokine is IFN $\alpha$ .

Another aspect of the invention pertains to a replication defective hepadnavirus particle, wherein a region of the S-gene of the hepadnavirus genome has been replaced with a therapeutic gene (e.g., a cytokine gene, such as such IFN $\alpha$ ) such that expression of the therapeutic gene is regulated by regulatory sequences of the preS/S-gene.

Pharmaceutical compositions comprising the replication defective hepadnavirus particle

and a pharmaceutically acceptable carrier or the replication defective hepadnavirus particle and a helper virus are also encompassed by the invention.

Yet another aspect of the invention pertains to a method of producing therapeutic replication defective hepadnavirus particles at a titre level suitable for therapeutic use.

5 The method involves:

co-transfecting hepatocytes with:

- 10 (i) replication defective hepadnavirus constructs, wherein a region of the S-gene of the hepadnavirus DNA has been replaced with a gene encoding a therapeutic gene such that expression of the gene encoding a cytokine is regulated by regulatory sequences of the preS/S-gene; and
  - (ii) a helper construct;
- culturing the hepatocytes until infectious viral particles are produced; and recovering the infectious viral particles.

In a preferred embodiment, the hepatocytes are replaced by a hepatoma cell line.

15

#### **Brief Description of the Drawings**

Figure 1A is a schematic diagram depicting the plasmid pCD16 expressing wild type DHBV, pregenomic DHBV-RNA displaying important cis-elements, and DHBV proteins.

20

Figure 1B is a schematic diagram depicting three DHBV recombinant transfer plasmids. In the first plasmid, rDHBV-S-GFP (rDHBV-S-GFP/IFN), the transgene replaces the S-gene of DHBV. In the second plasmid, rDHBV-core-GFP (rDHBV-core-GFP/IFN), the transgene replaces the core-gene of DHBV. The third plasmid is the pCD4 encapsidation deficient DHBV helper plasmid. Viral gene products lacked by the first and second plasmids are provided by cotransfection of the third, helper plasmid.

25

Figure 2 shows plasmid constructs used for the production of recombinant hepadnaviruses. The parental plasmids pCH-9/3091 (HBV) and pCD16 (DHBV) are based on terminally redundant hepadnavirus genomes (thick black lines) functionally mimicking the circular DNA genomes formed by reverse transcription of the RNA pregenomes (sinuous lines with A(n) representing the poly(A) tails). Numbers refer to nucleotide positions. The replication control regions (heavy black lines), encompassing HBV nucleotides 2360 to 40 and DHBV nucleotides 2100 to 2800, include *cis* signals for pregenomic RNA synthesis and maturation, and for RNA encapsidation and reverse transcription. These are continuous on the authentic circular viral genomes and partially duplicated here to create the terminal elements required for replication of the linearized genomes. Transcription start sites are indicated by the attached arrows, authentic viral

30

35

genes by the open bars with the gene designations inside. The positions of the transgenes in the recombinant plasmids are shown by the hatched boxes. Synthesis of the pregenomic RNAs is driven by a cytomegalovirus-IE enhancer/promoter element (marked CMV), whereas subgenomic RNAs, which encode the preS/S and the S envelope proteins and, for HBV, the X protein, are produced from internal promoters. In the RNA pregenomes,  $\epsilon$  denotes a 5'-proximal stem-loop that, in the case of DHBV, acts together with a second region (box marked R II) as an encapsidation signal. The 5'-terminal part of  $\epsilon$  (HBV up to nucleotide 3142, DHBV up to nucleotide 2579) is deleted in the helper constructs used to provide the missing gene products in trans. In pCH-S-GFP, a fragment encompassing the S gene was replaced by a DNA fragment encoding GFP fused to the first three amino acids of S. In pCD-16-S-GFP and pCD-16-S-IFN, DNA fragments encoding GFP and duck IFN, respectively, replace the KpnI to BstEII fragment encompassing the DHBV S gene.

Figure 3 is a dot-blot analysis showing virion formation after cotransfection of DHBV transfer and helper plasmids into LMH cells. Cotransfection of the recombinant rDHBV-S-GFP plasmid, in which the S-gene is replaced by a GFP gene, with the helper plasmid which trans-complements the lacking viral envelope and P-proteins into LMH cells, resulted in virion formation. Enveloped virions were analyzed on a dot-blot membrane with DHBV- and GFP-specific probes.

Figure 4A-D are photographs of hepatocytes depicting the transduction of primary hepatocytes by recombinant hepadnaviruses. Primary duck hepatocytes were infected at various multiplicities of infection with rDHBV-GFP, a recombinant DHBV that carries a GFP gene under the control of the DHBV S-promoter. GFP expression is shown (200-fold magnification) at day 6 post infection resulting from infection for 6 hours at a multiplicity of infection of 6 (Figure 4A), 25 (Figure 4B) or 100 (Figure 4C) or at a multiplicity of infection of 100 for 24 hours (Figure 4D).

Figure 5A-C depict the results from an experiment demonstrating that recombinant DHBV transferring an IFN gene interferes with the establishment of DHBV infection *in vivo*. Primary duck hepatocytes were infected with replication competent wildtype DHBV, and coinfecting with recombinant DHBV which carried a gene coding for a duck homolog of alpha interferon (rDHBV-IFN) or with rDHBV-GFP as a negative control. Success of infection was monitored (A) for release of progeny DHBV by DNA dot-blot (Figure 5A), and for structural DHBV proteins in cell lysates by Western blot (Figure 5B). Figure 5C is a graph showing a quantitative evaluation of the time course of DHBV production (DHBV-DNA equivalents). Coinfection with



rDHBV-IFN interfered with the establishment of a productive DHBV infection as effectively as interferon protein added at a dose showing maximal inhibition.

Figure 6A-C are photographs demonstrating that recombinant DHBV  
5 superinfects DHBV infected hepatocytes. Productively DHBV-infected hepatocytes were incubated with rDHBV-GFP (MOI of 50). After 6 days, cells were investigated for GFP fluorescence (Figure 6A), and stained for DHBV S-protein using a red-fluorescent TRITC-labeled secondary antibody (Figure 6B). As confirmed by the overlay (Figure 6C), GFP-expressing cells also stained positive for DHBV S-protein. Since the S-  
10 protein is expressed only from DHBV wildtype, but not from rDHBV-GFP, co-expression of GFP and S proves double-infection with both viruses.

Figure 7 is a graph demonstrating therapeutic gene transfer by recombinant DHBV. DHBV preinfected hepatocytes were superinfected at various multiplicities of  
15 infection with rDHBV-IFN, or with rDHBV-GFP as a negative control. The time course of progeny DHBV release is shown.

#### **Detailed Description of the Invention**

This invention pertains to methods and compositions relating to delivery of a  
20 foreign gene (*i.e.*, heterologous gene) into hepatocytes using a replication defective hepadnavirus particle. The invention is based, at least in part, on the discovery that replacement of nucleotide sequences in the S-gene region of hepadnavirus with a foreign gene, produce a replication defective hepadnavirus particle capable of infecting and expressing the foreign gene in hepatocytes at a level sufficient to interfere with the  
25 course of a viral infection in the hepatocytes. The data described herein demonstrate that the replication defective hepadnavirus particle acts as an effective delivery vector for a therapeutic gene to treat hepatic disorders.

The well-established duck hepatitis B virus (DHBV) model was used, which provides a readily available system for infection studies with primary hepatocytes as  
30 well as in whole animals, and efficacy in this model system is predictive of efficacy in human hepatitis B virus infection. Recombinant DHBV genomes were generated in which viral coding information was replaced by the green fluorescent protein (GFP) as a sensitive intracellular marker, or by a type 1 interferon (IFN) as a secreted protein with potential therapeutic applicability. Using these recombinant constructs, successful  
35 hepatocyte-specific transduction and expression of the transgenes *in vitro* and *in vivo* has been demonstrated herein (see the Examples).

Tissue-targeting, and in particular liver-targeting, is a major aim in gene therapy. Hepadnaviruses have distinct features that make them attractive candidates as vehicles

for this purpose. In contrast to most retroviral vectors, they efficiently infect quiescent liver cells. Different from adeno-, herpes-, retro- and parvoviruses, virus uptake is hepatocyte specific, as is gene expression from hepadnaviral promoter/enhancer elements. Furthermore, hepadnaviruses encode only few gene products that might  
5 induce an anti-vector immune response, which is one of the major problems with adeno- and herpesvirus vectors. Finally hepadnaviral DNA does not obligatorily integrate into the host cell genome, which is especially important for transient expression of an effector gene as preferred for the treatment of acquired liver diseases.

The data disclosed herein provides strong experimental evidence for the  
10 practicability of hepadnavirus-based, liver-directed gene transfer system. They show for the first time: (1) that it is possible to generate, after replacement of viral coding information, high titers of recombinant virus particles carrying a functional transgene; (2) that these particles infect their target cells with the same high hepatocyte-specificity as the parental virus leading to strong expression of the foreign gene *in vitro* and *in vivo*;  
15 and (3) that transduction of an interferon gene blocks establishment of hepadnavirus infection and also substantially reduces virus production from preinfected hepatocytes. With titers above  $10^8$  of enveloped virus particles per ml of cell culture supernatant and the possibility to further concentrate virus stocks without loss of infectivity, the recombinant hepadnaviruses described herein compare favorably with other vector  
20 systems such as retro- or parvoviruses.

Hepadnaviral gene transfer was found to be hepatocyte-specific; furthermore, all hepatocytes could be transduced *in vitro*. Although the transduction rate was reduced in the case of preinfected hepatocytes, a still significant fraction of productively DHBV-infected cells could be transduced by rDHBV-GFP. These data were corroborated by the  
25 clear-cut inhibition of DHBV replication by rDHBV-IFN in co-infected, and, more importantly, also in DHBV preinfected liver cells. This latter fact indicates that there is no principal barrier to apply recombinant hepadnaviruses to the treatment of infectious liver diseases. Owing to their molecular properties, hepadnaviruses appear to be particularly suited for the transient liver-specific expression of foreign genes. Several  
30 important acquired liver diseases might be targeted by hepadnaviral vectors, including chronic infections by HBV or hepatitis C virus, which are among the most common and most severe viral infection of humans worldwide. Although the size of foreign DNA which can be integrated into recombinant hepadnaviruses is limited (e.g., to approximately 800 bp of inserted DNA, although additional DNA may be accepted  
35 when other nonessential viral DNA sequences are deleted elsewhere in the genome), numerous important effector genes fit into the restricted space on the hepadnaviral genome. These include genes coding for specific antisense-RNA or trans-dominant proteins, as well as most cytokine genes.

Systemic treatment with IFN alpha currently is the only approved therapy for chronic hepatitis B and C. Other cytokines such as IFN gamma or TNF alpha potentially suppress liver infections with viral and non-viral agents, such as malaria hepatic stages, but severe side effects prohibit their systemic high-dose application. Therefore, local  
5 expression after liver-directed gene-transfer using the recombinant hepadnaviral vectors provided herein may provide a more efficient and better tolerated alternative.

In one aspect, the invention pertains to a method for expressing a heterologous gene in hepatocytes. The method involves:

providing replication defective hepadnavirus particles at a titre level competent  
10 to infect hepatocytes, wherein a region of the preS/S-gene of the hepadnavirus genome has been replaced with the heterologous gene such that expression of the heterologous gene is regulated by regulatory sequences of the S-gene; and

infecting hepatocytes with the hepadnavirus such that the heterologous gene is delivered into the hepatocytes and expressed in the hepatocytes.

15 Preferably, the replication defective hepadnavirus particles are human hepatitis B virus particles.

In one embodiment, the heterologous gene is inserted into a region of the S-gene such that nucleotides encoding at least one amino acid of the S protein are fused in-frame to the 5' end of the heterologous gene. In another embodiment, the heterologous  
20 gene replaces a region of the S-gene at a site equivalent to the KpnI site at position 1290 of duck hepadnavirus. In still another embodiment, the heterologous gene replaces a region of the S-gene at a site equivalent to the KpnI site at position 1290 of duck hepadnavirus, and the heterologous gene is inserted such that nucleotides encoding at least one amino acid of the S protein are fused in-frame to the 5' end of the heterologous  
25 gene. In still another embodiment, the heterologous gene replaces a region of the S-gene, and the heterologous gene is inserted such that nucleotides encoding at least one amino acid of the S protein are fused in-frame to the 5' end of the heterologous gene. In yet another embodiment, the heterologous gene replaces the S-gene. In still another embodiment, the heterologous gene replaces the S-gene and at least part of the preS-  
30 region.

Preferred heterologous genes for expression in hepatocytes are genes encoding modulating agents (i.e., agents that modulate a viral infection of the hepatocytes or other disorder of the hepatocytes). Preferred modulating agents are cytokines. A particularly preferred cytokine is IFN $\alpha$  (Type I IFN).

35 Another aspect of the invention pertains to a method of treating a subject with a hepatic disorder. The method involves:

providing replication defective hepadnavirus particles at a titre level competent to infect hepatocytes of the subject with the hepatic disorder, wherein a region of the S-

gene of the hepadnavirus genome has been replaced with a therapeutic gene such that expression of the therapeutic gene is regulated by regulatory sequences of the preS/S-gene; and

5 infecting hepatocytes of the subject with the hepadnavirus particles such that the therapeutic gene is delivered into the hepatocytes and expressed in the hepatocytes at a level sufficient to treat the hepatic disorder.

Preferred hepatic disorders to be treated by the method include hepatitis B, hepatitis C, hepatocellular carcinoma, cirrhosis, steatosis, hemochromatosis, and inherited liver disorders.

10 Preferred therapeutic genes include genes encoding modulating agents, such as cytokines. Preferred cytokines include IFN $\alpha$ , IFN $\beta$ , IFN $\gamma$ , IL-18 and TNF $\alpha$ .

In one embodiment, the hepadnavirus particle is directly administered to the subject. In another embodiment, the hepadnavirus construct and a helper virus construct are cultured *in vitro* and the infectious particles produced from the culture are  
15 administered to the subject. In another embodiment, recombinant hepadnavirus particles are produced by a helper cell line, and are administered to the subject.

The invention also provides a method of treating a subject with a hepatitis infection. The method involves:

20 providing replication defective hepadnavirus particles at a titre level competent to infect hepatocytes of the subject with hepatitis, wherein a region of the S-gene of the hepadnavirus genome has been replaced with a gene encoding a cytokine such that expression of the gene encoding a cytokine is regulated by regulatory sequences of the preS/S-gene; and

25 infecting hepatocytes of the subject with the hepadnavirus such that the gene encoding a cytokine is delivered to the hepatocytes and expressed in the hepatocytes at a level sufficient to treat the hepatitis.

Preferably, the cytokine is IFN $\alpha$ . Alternatively, the cytokine can be, for example, TNF $\alpha$ , IFN $\beta$ , IL-18 or IFN $\gamma$ .

30 In a particularly preferred embodiment, the hepatitis infection is hepatitis B and the cytokine is IFN $\alpha$ .

Another aspect of the invention pertains to a replication defective hepadnavirus particle, wherein a region of the S-gene of the hepadnavirus genome has been replaced with a therapeutic gene (e.g., a cytokine gene, such as such IFN $\alpha$ ) such that expression of the therapeutic gene is regulated by regulatory sequences of the preS/S-gene.

35 Pharmaceutical compositions comprising the replication defective hepadnavirus particle and a pharmaceutically acceptable carrier or the replication defective hepadnavirus particle and a helper virus are also encompassed by the invention.

Yet another aspect of the invention pertains to a method of producing therapeutic replication defective hepadnavirus particles at a titre level suitable for therapeutic use.

The method involves:

co-transfecting hepatocytes with:

- 5 (i) replication defective hepadnavirus constructs, wherein a region of the S-gene of the hepadnavirus DNA has been replaced with a gene encoding a therapeutic gene such that expression of the gene encoding a cytokine is regulated by regulatory sequences of the preS/S-gene; and
- (ii) a helper construct;
- 10 culturing the hepatocytes until infectious viral particles are produced; and
- recovering the infectious viral particles.

In a preferred embodiment, the hepatocytes are replaced by a hepatoma cell line.

So that the invention may be more readily understood, certain terms are first  
15 defined.

As used herein, the term "hepadnavirus" refers to a member of the *Hepadnaviridae* family of viruses, including but not limited to, human hepatitis B virus, woolly monkey hepatitis virus (Lanford *et al.* (1998) *Proc. Natl. Acad. Sci. U.S.A.* 95: 5757-5761), duck hepatitis B virus (DHBV; Mandart *et al.*, (1984) *J. Virol.* 49: 782-792; 20 Mason *et al.*, (1978) *J. Virol.* 36: 829-836), heron hepatitis virus (Sprengel *et al.*, (1988) *J. Virol.* 62: 3832-3839), woodchuck hepatitis virus (Summers *et al.*, (1978) *Proc. Natl. Acad. Sci.* 75: 4533-4537), and ground squirrel hepatitis virus (Marion *et al.*, (1980) *Proc. Natl. Acad. Sci.* 77: 2941-2945). Examples of other hepadnaviruses within the scope of the invention include, but are not limited to, HBV strains infecting various  
25 human organs, including hepatocytes, exocrine and endocrine cells, tubular epithelium of the kidney, spleen cells, leukocytes, lymphocytes, e.g., splenic, peripheral blood, B or T lymphocytes, and cells of the lymph nodes and pancreas (*see e.g.* Mason *et al.*, (1989) *Hepatology.* 9: 635-645). The invention also applies to hepadnaviruses infecting non-human mammalian species, such as domesticated livestock or household pets.

30 As used herein, the term "heterologous gene" or "foreign gene" refers to any gene or DNA sequence that does not occur naturally in the hepadnavirus genome, and which is incorporated into the hepadnaviral genome. The term "heterologous gene" or "foreign gene" is also used to encompass a DNA molecule from an entirely different species, *e.g.*, a human DNA sequence, *e.g.*, the gene encoding human INF $\alpha$  which is  
35 incorporated into the hepadnaviral genome.

As used herein, the term "replication defective hepadnaviral particle" refers to a hepadnavirus with a packaging signal ( $\epsilon$ ), in which a portion of the hepadnavirus genome has been replaced by a heterologous gene. The heterologous gene replaces a

portion of the hepadnavirus genome which encode protein products essential for replication, and thereby renders the hepadnavirus incapable of replicating. Replication by the replication defective hepadnaviral particle is permissible with the help of a "helper virus" which can produce protein products that the replication defective

5 hepadnaviral particle is incapable of producing. In particular, the term "replication defective hepadnaviral particle" refers to a hepadnavirus in which at least a portion of the S-gene, which encodes envelope proteins, is replaced.

As used herein, the term a "region" or "portion" of a gene (e.g., the hepadnaviral S gene) refers to a length of nucleotide sequence of the hepadnavirus genome which is

10 replaced by a heterologous gene. Preferably the length of replaced nucleotide sequence is at least about 200, preferably at least about 300 or 400, and even more preferably about 500 or 600 base pairs in length. Replacement of up to 800 nucleotides has been demonstrated.

As used herein, the term "regulatory sequences" is art-recognized and intended to

15 include promoters, enhancers and other expression control elements (e.g., polyadenylation signals). Such regulatory sequences are known to those skilled in the art and are described in Goeddel, *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, CA (1990).

The term "titre level competent to infect" also refers to an amount (e.g., number

20 of viral particles per a specified volume) sufficient to infect hepatocytes when applied to the hepatocytes. Suitable titre levels are for example, at least  $3 \times 10^7$ /ml to  $2 \times 10^8$ /ml of culture supernatant.

As used herein, the term "S-gene" refers to a hepadnaviral gene which encodes the S protein, a surface component of the hepadnavirus envelope (env). Expression of

25 the S-gene is under the control of the SP2 promoter. Two additional surface proteins, which are also components of the envelope, are the Large (L) and Middle (M) proteins (these are derived from alternative start sites). The L protein is regulated by the SP1 promoter. The "preS" region encompasses the genetic region 5' of the S-gene, including the promoter and other transcriptional regulatory regions.

As used herein, the term "modulating agent" refers to a compound which alters the state of the hepatocyte, such as agents that alter or interfere with a viral infection of the hepatocytes or other disorder of the hepatocytes. Examples of modulating agents that can change the state of the hepatocyte include compounds which can eliminate or diminish a disease of the liver, for example, cytokines such as  $\text{INF}\alpha$ ,  $\text{INF}\beta$ ,  $\text{INF}\gamma$ , TNF

35 and IL-18. Other examples of modulating agents include those that alter the function of hepatocytes, for example, to improve enzyme metabolism.

As used herein, the term "treating" refers to a reduction, alleviation or amelioration of at least one adverse effect or symptom of a disease or disorder, e.g., a

disease or disorder associated with hepatitis B virus infection, for example hepatitis B, cirrhosis or hepatocellular carcinoma.

As used herein, the term "subject" is intended to include organisms that are capable of being infected by hepadnaviruses, included mammals and birds. Preferred  
5 subjects are mammals. Examples of subjects include humans, ducks, woodchucks, squirrels, monkeys, dogs, cats, mice, rats cows, horses, goats, and sheep.

As used herein, the term "hepatic disorder" refers to any disease associated with the liver. Examples of diseases within the scope of the invention include, but are not limited to, hepatitis B, hepatitis C, hepatocellular carcinoma, cirrhosis, steatosis,  
10 hemochromatosis, and inherited liver disorders.

As used herein, the term "therapeutic gene" refers to a gene which encodes a therapeutic polypeptide which reduces, alleviates or ameliorates at least one adverse effect or symptom of a hepatic disease or disorder. Examples of therapeutic genes within the scope of the invention include, but are not limited to cytokines such as,  
15  $\text{INF}\alpha$ ,  $\text{INF}\beta$ ,  $\text{INF}\gamma$ , TNF, IL-18, antisense oligonucleotides, or inhibitory peptides.

As used herein, the term "helper construct" or "helper virus" refers to a virus which can produce protein products that the replication defective hepadnaviral particle is incapable of producing. The "helper virus" provides every factor essential for replication and renders the replication defective hepadnaviral particle capable of  
20 replicating. An Example of a helper construct within the scope of the invention includes, but is not limited to, a hepadnavirus construct lacking the envelope packaging signal ( $\epsilon$ ), and the hepatitis B virus. An example of a helper construct for HBV is pCH3142, and for DHBV is pCD4 (described further in the Examples).

The molecular biology of hepadnaviruses and their infectious cycle has been well  
25 characterized (for reviews see e.g., Nassal *et al.*, (1993) *Trends Microbiol.* 1:221-228; Nassal, *et al.*, (1996) *J. Viral Hepat.* 3:217-226). Infectious virions contain a partially double-stranded circular DNA genome of only 3 - 3.2 kb in length, with the viral replication enzyme, P protein, covalently attached to the 5'-end of the long DNA strand. After entry into the host cell, the genome is delivered to the nucleus and transformed  
30 into a covalently closed circular DNA (cccDNA) that serves as a template for transcription of four classes of subgenomic and genomic RNAs. All the RNAs are translated into protein; the mRNA for the capsid and the P protein is, in addition, co-packaged with P protein into newly forming capsids where it is reverse transcribed by the enzyme into DNA. It is therefore termed RNA pregenome, or pregenomic RNA. A  
35 number of cis-elements have been identified which are required to ensure efficient production of genomic and subgenomic transcripts, and for packaging and reverse transcription of the pregenomic RNA. These include promoters and enhancers (Hirsch *et al.* (1991) *J. Virol.* 65:3309-3316; Schaller *et al.* (1991) *Curr. Topics Microbiol.*

*Immunol.* 168:21-39), the poly-adenylation signal, the RNA encapsidation signal  $\epsilon$  (Hirsch *et al.* (1991) *J. Virol.* 65:3309-3316; Junker Niepmann *et al.*, (1990) *Embo J.* 9:3389-3396), a less well defined DHBV-specific second element, region II (Calvert *et al.*, (1994) *J. Virol.* 68:2084-2090), and several copies of a direct repeat sequence (DR1, DR2 and DR1\*) (Lien *et al.*, (1987) *J. Virol.* 61:3832-3840; Molnar Kimber *et al.*, (1984) *J. Virol.* 51:181-191; Seeger *et al.*, (1991) *J. Virol.* 65:5190-5195). Further cis-elements, for example, the PET element (Huang, *et al.* (1994) *J. Virol.* 68:1564-1572), are involved in transcriptional regulation and intracellular transport.

Two major animal virus models are currently used as infection systems for HBV: the woodchuck hepatitis B virus (WHV; (Roggendorf *et al.*, (1995) *Intervirology* 38:100-112)) and the duck hepatitis B virus (DHBV; (Schodel *et al.*, (1991). In particular ducks provide a readily available system for infection studies in whole animals as well as in primary liver cells.

Gene delivery by a hepadnaviral vector requires generation of infectious, but preferentially replication defective recombinant virus particles. To generate infectious virus particles, recombinant pregenomic RNA must meet some requirements that limit the possibilities for inserting additional foreign sequences. The most important constraints are the small size and compact organization of the hepadnaviral genome that precludes simple insertion of additional sequences. An insertion may interfere with one or more of the numerous cis-elements that make up approximately 15% of the viral genome. Thus, replacement of coding information by a foreign gene may be suitable to generate a replication deficient recombinant virus.

In one aspect, the invention pertains to a method for expressing a heterologous gene in hepatocytes by providing replication defective hepadnavirus particles at a titre level competent to infect hepatocytes, wherein a region of the S-gene of the hepadnavirus genome has been replaced with the heterologous gene such that expression of the heterologous gene is regulated by regulatory sequences of the S-gene, and infecting hepatocytes with the hepadnavirus such that the heterologous gene is delivered into the hepatocytes and expressed in the hepatocytes.

The molecular biology of hepadnaviruses and their infectious cycle has been well characterized (for reviews see e.g., Nassal *et al.*, (1993) *Trends Microbiol.* 1:221-228; Nassal, *et al.*, (1996) *J. Viral Hepat.* 3:217-226). Infectious virions contain a partially double-stranded circular DNA genome of only 3 - 3.2 kb in length, with the viral replication enzyme, P protein, covalently attached to the 5'-end of the long DNA strand. After entry into the host cell, the genome is delivered to the nucleus and transformed into a covalently closed circular DNA (cccDNA) that serves as a template for transcription of four classes of subgenomic and genomic RNAs.



To generate infectious virus particles, recombinant pregenomic RNA must meet some requirements that limit the possibilities for inserting additional heterologous sequences. The most important constraints are the small size and compact organization of the hepadnaviral genome that precludes simple insertion of additional sequences. An  
5 insertion may interfere with one or more of the numerous cis-elements that make up approximately 15% of the viral genome.

Many strategies are known in the art to produce constructs of the hepadnavirus gene. The relevant sequences of the hepadnaviral genome and of the heterologous gene can be cleaved at appropriate sites with restriction endonucleases, isolated and ligated in  
10 vitro, using techniques known in the art. In the method of the invention, a region of the S-gene of the hepadnavirus gene is replaced with the heterologous gene. In preferred embodiments, the heterologous gene is inserted into a region of the preS/S-gene. In other preferred embodiments, the heterologous gene is inserted into a region of the  
15 preS/S-gene such that nucleotides encoding at least one amino acid of the S protein are fused in-frame to the 5' end of the heterologous gene. Preferably, the heterologous gene is operably linked with least one amino acid of the S protein. More preferably, the heterologous gene is operably linked with up to five to ten amino acids of the S protein. More preferably, the heterologous gene is operably linked with one, two, three amino  
20 acids of the S protein. Most preferably, the heterologous gene is operably linked with four amino acids of the S protein. Example 1 shows the construct which demonstrates the efficiency of operably linking four amino acids of the S protein with green fluorescent protein (GFP). When the construct was transfected into chicken hepatoma cell line (LMH) cells a bright green fluorescence was detected 48 hours post  
transfection, demonstrating efficient expression of GFP.

25 In preferred embodiments, the heterologous gene replaces a region of the S-gene at a site equivalent to the KpnI site at position 1290 of duck hepadnavirus. In other preferred embodiments, the heterologous gene is inserted into the preS/S-gene after the authentic AUG. Accordingly, the nucleotide sequence of any hepatitis virus, such as human hepatitis B virus may be used and the equivalent KpnI site used to clone the  
30 heterologous gene. Alternatively, the nucleotide sequence of any hepatitis virus, such as human hepatitis B virus may be used and the heterologous gene inserted after the authentic AUG in either the preS/S-gene.

The size of the heterologous gene used to replace the S-region is preferably about 200 up to about 1200 nucleotides. More preferably, the size of the heterologous gene  
35 used to replace the S-region is about 300 up to 800 nucleotides. Most preferably, the size of the heterologous gene used to replace the S-region is about 600 nucleotides.

In preferred embodiments, the heterologous gene encodes a modulating agent which modulates the state of the liver once the replication defective hepadnavirus

particles containing the heterologous gene is expressed in the liver. Examples of modulating agents include compounds that can change the state of the liver include those which can eliminate, ameliorate or improve a disease of the liver. Other examples of modulation include those that alter the function of hepatocytes, for example, to  
5 improve enzyme metabolism. Modulating agents include, but are not limited to cytokines, blood factors, enzymes, antisense nucleic acids, and transdominant proteins. In preferred embodiments, the modulating agent is a cytokine. In still more preferred embodiments, the cytokine is  $INF\alpha$ .

In another aspect the invention provides a method of treating a subject with a  
10 hepatic disorder by providing replication defective hepadnavirus particles at a titre level competent to infect hepatocytes of the subject with the hepatic disorder, wherein a region of the S-gene of the hepadnavirus genome has been replaced with a therapeutic gene such that expression of the therapeutic gene is regulated by regulatory sequences of the preS/S-gene; and infecting hepatocytes of the subject with the hepadnavirus particles  
15 such that the therapeutic gene is delivered into the hepatocytes and expressed in the hepatocytes at a level sufficient to treat the hepatic disorder. As demonstrated in the examples, intravenous injection of infectious replication defective hepadnavirus particles is sufficient to deliver the particles into hepatocytes *in vivo* and to achieve expression of the heterologous gene in the hepatocytes.

20 Hepatic disorder that can be modified by modulating agents include transient hepatic disorder which require treatment with the replication defective hepadnavirus particles wherein a region of the S-gene of the hepadnavirus genome has been replaced with a therapeutic gene only until the hepatic disorder has been ameliorated. Examples of transient hepatic disorders include, but are not limiting to hepatitis B, hepatitis C,  
25 cirrhosis, hepatocellular carcinoma, and malaria. Other hepatic disorders that can be treated using the method of the invention include, but are not limited to hyperammonemia, infantile cholestasis and hepatomegaly.

In order to directly demonstrate the potential of hepadnaviral vectors for liver-specific gene delivery, recombinant DHBV and HBV particles carrying a foreign gene  
30 were generated, and used to infect primary duck or human hepatocytes. Using the green fluorescent protein (GFP) as a marker, several recombinant DHBV and HBV genomes were constructed, some of which yielded substantial titers of secreted recombinant virus (rDHBV or rHBV). These viruses infected primary duck or human hepatocytes in a species-specific manner and efficiently delivered the foreign gene as demonstrated by  
35 GFP fluorescence. As a candidate therapeutic agent a homologous recombinant DHBV carrying the duck type I interferon (DulFN) (Schultz *et al.*, (1995) *Virology* 212:641-649) was generated. Infection of primary hepatocytes from endogenously infected ducks with this recombinant reduced DHBV replication by more than 90%.

## Examples

The present invention is further illustrated by the following examples which should not be construed as limiting in any way. The contents of all cited references, including literature references, issued patents, and published patent applications, as cited throughout this application are hereby expressly incorporated by reference.

Methodologies and reagents utilized in the following Examples are described below:

### **I. DHBV Methodologies**

DHBV Plasmid constructs. All DHBV constructs are based on plasmid pCD16 which contains a terminally redundant DHBV genome (subtype 16) (Mandart, E. et al. (1984) *J. Virol.* 49:782-792) (3317 bp, nucleotides 2520 to 2816) under control of the CMV immediate early promoter/enhancer (Fig. 1A-B and 2)(Obert, S. et al. (1996) *EMBO J.* 15:2565-2574; Bartenschlager, R. (1990) Thesis, University of Heidelberg). The helper plasmid pCD4 lacks part of the 5 encapsidation signal  $\epsilon$  (Fig. 1A-B and 2) and is therefore encapsidation-deficient (Bartenschlager, R. (1990) Thesis, University of Heidelberg). The marker construct pCD16-S-GFP was obtained by replacing a DHBV-DNA fragment containing the S gene (from Kpn I, nucleotide position 129D, to BstE II, nucleotide position 1847; see Fig. 1A-B and 2) with a PCR fragment (733 nucleotides) encoding a fluorescence-enhanced, red-shifted GFP prepared from plasmid pTR-UF5 (Zolotukhin, S., et al. (1998) *J. Virol.* 70:4646-4654) with primers introducing terminal Kpn I and BstE II sites. pCD16-S-IFN was obtained analogously by inserting a PCR-derived fragment (591 nucleotides) encoding the complete duck type 1 IFN gene (Schultz, U. et al. (1995) *J. Virol.* 70:4646-4654). For production of recombinant duck IFN protein, the IFN gene was cloned into a pUC based CMV-IE promoter controlled expression vector (pCD IFN).

Production of recombinant DHBV stocks. Chicken hepatoma LMH cells (Condreay, L.D. et al. (1990) *J. Virol.* 64:3249-3258) at 30-40% confluency were cotransfected using the calcium-phosphate method with 50 $\mu$ g of the respective recombinant pCD16 plus 25 $\mu$ g plasmid pCD4 per 15 cm dish. Cell culture medium containing recombinant virions was collected from days 3 to 5 post transfection, concentrated 10- to 50-fold by precipitation with 6.5% polyethylene glycol 20.000/0.9% NaCl at 0°C, and stored in PBS/10% glycerol at -20°C until further use. Virus titers, measured as enveloped DNA containing particles, were determined by density gradient centrifugation and subsequent dot blot analysis relative to a DHBV-DNA standard (Obert, S. et al. (1996) *EMBO J.* 15:2565-2574).

Isolation of primary hepatocytes for DHBV experiments. Primary duck hepatocytes (PDH) were isolated from 2- to 3-week-old Peking ducks by a standard two step collagenases perfusion via the portal vein and subsequent differential centrifugation (50 x g), seeded at a density of  $2.5 \times 10^5$  cells/cm<sup>2</sup>) and maintained as described (Hild, M. et al. (1998) *J. Virol.* 72:2600-2606). DHBV-positive PDH were obtained analogously from ducks experimentally infected the first day after hatching with 100 µl duck serum containing  $10^9$  DHBV16-virions. Primary mouse hepatocytes were isolated from 16 to 20-week old CH57BL/6 mice, seeded onto collagen type 1 (Sigma Aldrich, Irvine, CA, USA) coated tissue culture plates in maintenance medium/10% FCS at  $4 \times 10^5$  cells/cm<sup>2</sup> and maintained without FCS as described (Hild, M. et al. (1998) *J. Virol.* 72:2600-2606). Endothelial cells and Kupffer cells in the hepatocyte cultures were identified on the basis of their uptake of a TRITC labeled acetylated low-density lipoprotein (Dil-Ac-LDL; Paesel & Lorel, Duisburg, Germany (Irving, M.G. et al. (1984) *Gastroenterology* 87:1233-1247)) and by phagocytosis of 1µm amine-modified yellow-green fluorescent latex beads (Sigma-Aldrich Chemie, Deisenhofen, Germany), respectively.

DHBV infection and gene transfer by recombinant DHBV. Primary hepatocytes were incubated, at day 2 post plating, for 24 hours with rDHBV, or wildtype DHBV from a DHBV15 positive duck serum, diluted in maintenance medium at the desired multiplicity of infection. GFP expression was monitored by fluorescence microscopy using a standard FITC-filter set with excitation by blue light (488 nm). For *in vivo* infections ducklings were inoculated at day one after hatching with  $10^9$  rDHBV-GFP virions. At day 7 post-infection, animals were anaesthetized and perfused via the portal vein with cold 4% paraformaldehyde/0.25% glutaraldehyde. Livers were removed, post-fixed for 24 hours in perfusion buffer, saturated with 30% sucrose and sectioned serially (10 - 15µm) on a freezing microtome. In addition, primary hepatocytes were isolated and analyzed as described above.

Coinfection of DHBV-positive pDH with recombinant DHBV-IFN.

DHBV-negative PDH were simultaneously infected with serum-derived DHBV (multiplicity of infection of 25) plus rDHBV-IFN (multiplicity of infection of 50) or plus rDHBV-GFP (multiplicity of infection of 50). DHBV-positive PDH were infected accordingly. Cell lysates were analyzed for Intracellular DHBV proteins by Western blot analysis (described below), and release of progeny DHBV virus into the cell culture medium was quantitatively determined by DHBV-DNA dot blot analysis. As a positive control, DHBV-infected PDH were incubated with a diluted preparation of recombinant duck IFN protein obtained in the form of cell culture medium of LMH cells transfected with plasmid pCD-IFN at a dose which had proven in previous experiments sufficient to

maximally inhibit DHBV replication. IFN protein was added at day 3 post infection at which time transgene expression from rDHBV-GFP was first detectable.

#### Immunofluorescence staining and Western blot analysis of intracellular DHBV antigens.

- 5 For immunodetection of intracellular DHBV antigens a polyclonal rabbit antiserum against the DHBV core-protein (Schlichl, H.J. et al. (1987) *J. Virol.* 61:3701-3709), or monoclonal antibody MAb 7C.12 (Pugh, J.C. et al. (1995) *J. Virol.* 59:4814-4822) recognizing the DHBV S-protein were used and detected with an appropriate fluorescence-labeled secondary antibody. For direct detection of intracellular viral
- 10 proteins,  $10^6$  PDH were lysed by the addition of 250  $\mu$ l of protein sample buffer (Hild, M. et al. (1998) *J. Virol.* 72:2600-2606) after removal of cell culture medium. In addition, cytoplasmic lysates from  $10^7$  transfected LMH cells were incubated with rabbit antiserum against DHBV pre S-protein (Schöcht, H.J. et al. (1987) *J. Virol.* 61:2280-2285) or with rabbit antiserum against GFP (Clontech, Palo Alto, CA, USA) antibodies
- 15 and immunoprecipitated proteins were released by boiling the beads in 50  $\mu$ l sample buffer (Schöcht, H.J. et al., *supra*). 25  $\mu$ l each were separated by 10% SDS-PAGE, blotted to a positively charged nylon membrane, immunostained with the polyclonal antisera against DHBV core- (Schlichl, H.J. et al., *supra*), S- (Schöcht, H.J. et al., *supra*) and pre S-proteins (Schlichl, H.J. et al., *supra*) or against GFP, and visualized using the
- 20 ECL-system (Amersham, Cleveland, Ohio, USA) essentially as described (Hild, M. et al. (1998) *J. Virol.* 72:2600-2606).

## **II. HBV Methodologies**

- 25 HBV Plasmid constructs. HBV constructs contained under control of the CMV immediate early promoter/enhancer a terminally redundant genome of HBV, subtype ayw 1 (pCH-9/3091, HBV nucleotides 3091 to 84, numbering from the core initiation codon) (Nassal, M., et al. (1990) *Cell* 63: 1357-1363). The helper construct pCH3142 (Bartenschlager, R. (1990) Thesis, University of Heidelberg) lacked part of the 5'
- 30 encapsidation signal  $\epsilon$  and is therefore encapsidation-deficient (Fig. 2).

- The marker construct pCH-S-GFP was obtained by replacing DNA fragments containing the S gene (from XhoI, nucleotide position 1409, to NsiI, nucleotide position 2347) with a PCR fragment (733 nucleotides) encoding a fluorescence-enhanced, red-shifted GFP prepared from plasmid pTR-UF5 (Zolotukhin, S. et al. (1996) *J. Virol.* 70: 4646-4654) with expression being expected to be driven by the S promoter (see Fig. 2).
- 35

Production of recombinant HBV stocks. Human hepatoma HuH7 cells (Chang, C.M. et al. *EMBO J.* 6: 675-680) were cotransfected with rHBV and helper construct using the

same methodologies employed in the production of recombinant DHBV stocks, above. Wildtype HBV was produced by transfecting HuH7 cells with plasmid pCH-9/3091.

Isolation of primary hepatocytes for HBV experiments. Surgical human liver biopsies

were obtained after informed consent of the donor and perfused via a large branch of the portal vein after disclosure of small vessels. Primary hepatocytes were isolated by a standard two step collagenase perfusion and subsequent differential centrifugation (at 50 x g), as described above in the procedures for the isolation of primary hepatocytes for DHBV experiments.

HBV infection and gene transfer by recombinant HBV. Primary human hepatocytes were incubated for 24 hours with rHBV-S-GFP or wildtype HBV, diluted in maintenance medium at a multiplicity of infection of 500, at day 1 post plating. GFP expression was monitored as described in the DHBV infection experiments (above).

Immunofluorescence staining and Western blot analysis of intracellular HBV antigens

For immunodetection of intracellular HBV antigens, polyclonal rabbit antisera against the HBV core-protein were used and detected with an appropriate fluorescence-labeled secondary antibody. For direct detection of intracellular HBV proteins, infected human hepatocytes were lysed and subjected to Western analysis under similar conditions to those utilized for the DBHV-infected PDH cells (above).

**Example 1: Preparation of Duck Hepatitis B Virus Plasmid Constructs**

Plasmid constructs used for transfection into cells were prepared from the parental plasmid, pCD16, which contains an overlenth DHBV 16 genome (nucleotide 2520 to 3021/1 to 2816) under control of the CMV immediate early promoter (Bartenschlager, R. et al. (1990) *J. Virol.* 64:5324-5332). Upon transfection of the plasmid into the chicken hepatoma cell line LMH (Condreay *et al.*, (1990) *J. Virol.* 64:3249-3258), genomic transcripts starting at position 2529 and terminating around nucleotide 2800 (Figure 1A) are produced that give rise to the formation of infectious DHBV particles (Obert *et al.*, (1996) *EMBO J.* 15:2565-2574). pCD4 (Bartenschlager, R. et al. (1990) *J. Virol.* 64:5324-5332) is a derivative of pCD16 containing an overlenth DHBV genome (nucleotides 2589 to 2845) lacking the 5' encapsidation signal Dε (Figure 1B); it provides all gene products in *trans* but is itself encapsidation, and therefore, replication-deficient (analogous HBV constructs have been described (Junker Niepmann *et al.*, (1990) *EMBO J.* 9:3389-3396).

As a marker, a fluorescence-enhanced variant (S65T/F64L, humanized codon usage) of the green fluorescent protein (GFP) present in plasmid pTR-UF5 (Zolotukhin

*et al.*, (1996) *J. Virol.* 70:4646-4654), was used. Using appropriate primers, the GFP gene was modified by PCR to carry additional terminal restriction sites. These allowed cloning of the GFP gene between the Kpn I (nucleotide position 1290) and BstE II (nucleotide position 1847) sites in plasmid pCD16, thus replacing the S-gene (Figure 1B). With 3196 base pair (bp), the resulting rDHBV-S-GFP genome is 175 bp longer than authentic DHBV (3021 bp). Alternatively, the core gene fragments Xba I (nucleotide position 2662) to Hinc II (nucleotide position 141), or Xba I (nucleotide position 2662) to Bgl II (nucleotide position 391) were replaced; this left the Dε signal and the PET element intact. To provide a functional poly-adenylation signal, the canonical AAUAAA motif and following GU-rich sequence were also maintained. The foreign protein encoded by the resulting rDHBV-core-GFP genomes of 3299 bp and 3049 bp is a fusion of GFP to the N-terminal core protein amino acids 1 to 5 and 39 to 56.

In the plasmid construct, rDHBV-S-GFP, the GFP gene replaces essentially the entire S-gene except for its first four codons. Transcription of a subgenomic mRNA from the recombinant DHBV genome as well as from the pCD16-S-GFP expression construct occurs from the S and, possibly, the preS promoter (Buscher *et al.*, (1985) *Cell* 40:717-724); in the latter case a preS/GFP fusion might be produced. For the core replacement constructs, a GFP encoding, in this case, genomic mRNA is produced from the strong CMV-IE promoter in the pCD16-core-GFP plasmid, and from the genomic promoter after recombinant virus formation. For the sake of preserving important *cis*-elements in the 5'-part of the pregenome, the core replacement constructs encode an N-terminal fusion of GFP to amino acids 1 to 5 and 39 to 56 of the DHBV core protein.

To test for sufficient expression of functional GFP, the pCD16-S-GFP and pCD16-core-GFP constructs were transfected into LMH cells and monitored for GFP fluorescence. This resulted in bright green fluorescence easily detectable 24 hours post transfection with the core-replacement constructs, and 48 hours post transfection with the S-replacement constructs. The result demonstrated that functional mRNAs and GFP proteins were produced from the CMV-IE promoter (pCD16-core-GFP) as well as from the endogenous preS/S promoters (pCD16-S-GFP). GFP-specific Western blot analysis of extracts from pCD16-S-GFP transfected cells showed two closely spaced bands of approximately 30 kDa. Most probably these represent GFP protein and a fusion of GFP to the first 4 amino acids of the S open reading frame arising from translation initiation at its authentic AUG codon. No larger products representing a putative preS-GFP fusion protein could be detected.

As a gene of potential therapeutic use, PCR-derived fragments encoding the complete duck Type I IFN gene (DuIFN) (Schultz *et al.*, (1995) *Virology* 212:641-649) were introduced into the same locations as the S-gene or the core gene in the DHBV

plasmid. The corresponding recombinant genomes are 3055 bp (rDHBV-S-IFN), and 3158 bp or 2908 bp (rDHBV-core-IFN) in length.

To produce recombinant DuIFN, the complete DuIFN gene was cloned into an eukaryotic expression vector under the control of a CMV-IE promoter.

5

Additional description of the construction and production of recombinant DHBV is as follows:

As a basis for constructing recombinant DHBV (rDHBV) genomes, the plasmid pCD16 was used, which upon transfection gives rise to the production of infectious DHBV particles (Obert, S. et al. (1996) *EMBO J.* 15:2565-2574)(see Fig. 2). Care was taken not to affect parts of the DHBV genome harboring cis-acting control elements, such as the well characterized replication control region, which directs synthesis, packaging, and reverse transcription of the RNA pregenome (Seeger, C. & Hu, J. (1997) *Trends in Microbiol.* 5:447-450; Nassal, M. & Schaller, H. (1996) *J. Viral. Hepat.* 3:217-226; Ganem, D., Hepadnaviridae: The Viruses and Their Replication, in *Fields Virology* (eds. Fields, B.N., Knipe, D.M & Howley, P.M), pp. 2703-2737 (Lippincott-Raven Publishers, Philadelphia, 1996)) and several less well defined control elements primarily involved in RNA maturation (Obert, S., *supra*; Huang, J. & Liang, T.J. (1993) *Mol. Cell. Biol.* 13:7476-7486; Huang, M. & Summers, J. (1994) *J. Virol.* 68:1564-1572; Clavert, J. & Summers, J. (1994) *J. Virol.* 65:2084-2090) (see Fig. 2). Initial studies indicated that replacement of the small envelope (S) gene by foreign sequences, and maintaining genome size with respect to the wild type, was the most successful approach. Two analogous C gene replacement constructs failed to produce enveloped DHBV particles, although their overall genome size was within the same limits and no known cis-elements were affected. In the constructs selected for further use, appropriately end-modified fragments encoding GFP (Zolotukhin, S. et al. (1998) *J. Virol.* 70:4646-4654)(pCD16-S-GFP) and duck IFN type 1 (Schultz, U. et al. (1995) *Virology* 212:641-649)(pCD16-S-IFN) were fused to the first four codons of the DHBV S-gene with expression being expected to occur from the preceding DHBV S promoter (Fig. 2).

Upon transfection of plasmid pCD16-S-GFP a bright GFP fluorescence became detectable about 48 hours post transfection. GFP-specific Western blot analysis of extracts from pCD16-S-GFP transfected LMH cells showed two closely spaced bands of approximately 30 kDa, probably representing GFP and a DHBV-S/GFP-fusion. An additional RNA, initiating from the pre-S promoter, might serve for the expression of a preS/GFP fusion protein. However, no larger products corresponding to such a fusion protein were detected.



S gene replacement destroys the S, L and polymerase open reading frames. For production of recombinant virus in transfected chicken hepatoma cells (Condreay *et al.*, (1990) *J. Virol.* 64:3249-3258), the corresponding proteins were transcomplemented by the cotransfected encapsidation deficient helper pCD4 (Schlicht *et al.*, (1989) *Cell* 56:85-92; Bartenschlager, R. *et al.* (1990) *J. Virol.* 64:5324-5332). This resulted in the production of enveloped recombinant DHBV (rDHBV) as verified by CsCl density gradient centrifugation (Obert *et al.*, (1996) *EMBO J.* 15:2565-2574). Virus titers of rDHBV-GFP and rDHBV-IFN varied between  $3 \times 10^7$  and  $2.5 \times 10^6$ /ml in different experiments, comparable to those of wild-type DHBV produced by transfection of LMH cells (Obert *et al.*, (1996) *EMBO J.* 15:2565-2574). Virus could be concentrated by polyethylene glycol precipitation up to 50-fold without loss. These data proved that enveloped, recombinant virions with replacement of viral sequences by foreign genes could efficiently be produced.

#### 15 **Example 2: Production of Recombinant Duck Hepatitis B Virus Stocks**

High titres of recombinant DHBV viral stocks were produced by transfection of recombinant pCD16 plasmids into LMH cells. Since the S and core gene replacements destroy essential viral genes, to transcomplement the according gene products of the DHBV transfer plasmids (Horwich *et al.*, (1990) *J. Virol.* 64:642-650; Schlicht *et al.*, (1989) *Cell* 56:85-92) the encapsidation deficient helper plasmid pCD4 (Figure 1B), in which part of the 5' -terminal  $\Delta\epsilon$  signal is deleted, was also used. Confluent LMH cells were split 1:8 the day before transfection in order to reach 30-40% confluency at transfection. 50  $\mu$ g of the respective recombinant pCD16 plasmid and 25  $\mu$ g of the helper plasmid pCD4 to transcomplement lacking DHBV proteins were cotransfected per 15 cm dish, using the standard calcium-phosphate method. DNA-precipitates were washed off after overnight incubation (day 1 post transfection) and cell culture medium was exchanged again the next day (day 2). Cell culture medium containing recombinant DHBV virions was harvested at day 5 and day 8 post transfection. Virus stocks were concentrated by precipitation with polyethylene glycol 20.000 (final concentration 6.5%) at 0°C and stored in PBS /10% glycerol at -20°C until further use. Repeated freezing and thawing was avoided.

Cotransfection of the pCD16-core-GFP constructs and helper plasmid pCD4 into LMH cells resulted in bright green fluorescence that was easily detectable 24 hours post transfection. With pCD16-S-GFP and helper plasmid pCD4 constructs, development of strong fluorescence took about 48 hours.

Formation of recombinant virions was identified by sedimentation in a CsCl gradient which separates naked DNA-containing DHBV core particles from enveloped virions. 2 ml aliquots of cell culture media or 200  $\mu$ l aliquots of concentrated virus

stocks diluted in 1.8 ml PBS were layered on top of CsCl step gradients (bottom to top: 0.5 ml each of CsCl density 1.4, 1.3 and 1.2 and 20 % sucrose in H<sub>2</sub>O) and ultracentrifuged (3.5 h at 4°C, 58000 r.p.m. in an SW60 rotor) to separate enveloped virus particles from naked cores (Obert *et al.*, (1996) *EMBO J.* 15:2565-2574). Twelve  
 5 180 µl fractions (bottom to top) were collected and DNA was detected by dot blot hybridization with a <sup>32</sup>P labeled full length DHBV- or GFP-probe (specific activity ~10<sup>8</sup> c.p.m./ µg).

Cell culture medium harvested at day 5 and at day 8, subjected to sedimentation in a CsCl step gradient, separated naked DNA-containing DHBV core particles  
 10 (fractions 1 to 4, bottom to top) from enveloped virions (fractions 6 to 8) as shown in Figure 3 (Obert *et al.*, (1996) *EMBO J.* 15:2565-2574). Individual fractions were then analyzed by DNA dot blot using DHBV and GFP specific probes. For rDHBV-S-GFP, DNA hybridizing to both the DHBV and the GFP probe was clearly detectable in fractions characteristic for enveloped virions (Figure 3), indicating that recombinant  
 15 virions had been generated. By contrast, both core GFP constructs failed to produce clearly detectable signals in the corresponding fractions, and hence were not used in further experiments.

Virus titres, measured as enveloped DNA containing particles, were determined by quantitative comparison with a dilution series of a DHBV-DNA standard on the same  
 20 blot using a phosphorimager (Molecular Dynamics, Sunnyvale, Ca., USA). For the rDHBV-S-GFP recombinant virus, the titer of DNA containing enveloped particles was determined by quantification of the signal intensities relative to a dilution series of pCD16 DNA standard on the same blot and found to be between 3x10<sup>7</sup> and 2x10<sup>8</sup> ml in different experiments. Thus, the titres of recombinant viruses achieved by  
 25 transcomplementation are comparable to those of wildtype virus from transfected LMH cells (Obert *et al.*, *supra*). Further concentration of virus stocks could easily be achieved by polyethylene glycol precipitation. These experiments demonstrated that replacing a 550 bp DHBV fragment with a foreign gene of about 750 bp did not interfere with enveloped particle formation. The negative results with the core-GFP constructs, on the  
 30 other hand, emphasize the importance of the appropriate location for the gene replacement.

### **Example 3: Isolation of Primary Duck Hepatocytes**

Primary duck hepatocytes (pDH) were isolated by standard methods. Briefly,  
 35 livers from two to four week old ducklings were perfused by two step collagenase perfusion technique via the portal vein, hepatocytes were sedimented three times at 50 g and seeded at a density of 10<sup>6</sup> cells per ml (2.5x10<sup>5</sup>/ cm<sup>2</sup>) in 6- or 12-well plates essentially as described before (Galle *et al.*, (1989) *Hepatology* 10:459-465). Cells were

maintained at 37°C, 5% CO<sub>2</sub> in supplemented Williams E medium (50 µg/ml gentamycin, 50 µg/ml streptomycin, 50 IU/ml penicillin, 2.25 mM L-glutamine, 0.06% glucose, 23 mM HEPES- pH7.4, 4.8 µg/ml hydrocortisone, 1 µg/ml inosine, 1.5% DMSO). DHBV positive pDH were obtained from ducklings infected with 100 µl  
5 DHBV16 positive duck serum (10<sup>10</sup> DNA genome equivalents / ml) the first day after hatching of which serum samples obtained at day 7 and day 14 proved DHBV-positive by DNA dot blot analysis.

Non-parenchymal liver cells (especially Kupffer cells and sinusoidal endothelial cells) have been reported to make up 3-20% of all cells in culture after collagenase  
10 perfusion and differential sedimentation of hepatocytes (Johnston *et al.*, (1994) *Hepatology* 20:436-444). Endothelial cells and some Kupffer cells in the pDH cultures were identified on the basis of their receptor-mediated uptake of Dil-Ac-LDL (Paesel & Lorei, Duisburg, Germany (Irving *et al.*, (1984) *Gastroenterology* 87:1233-1247) after an incubation for 1-2 hours, that is, acetylated low-density lipoprotein labeled with  
15 TRITC as a fluorescent dye.

According to the protocol described, primary hepatocytes were isolated from 16 to 20-week old CH57BU6 mice, seeded onto collagen type I (Sigma Aldrich, Irvine, Ca., USA) coated tissue culture plates in maintenance medium /10% FCS at a density of 4 - 5 x 10<sup>5</sup> cells / ml (10<sup>5</sup>/ cm<sup>2</sup>) and maintained as described above.

20

#### **Example 4: Infection of Isolated Primary Duck Hepatocytes with Recombinant Duck Hepatitis B Virus Particles**

To examine the infectivity of recombinant virions, primary duck hepatocytes were infected with rDHBV during the first days in culture (usually day 2 post plating).  
25 rDHBV was diluted in maintenance medium to the desired multiplicity of infection (measured as DNA-containing enveloped DHBV particles / cell) and incubated on pDH for 24 hours. As an infection control, duck serum containing 10<sup>10</sup> / ml DNA genome equivalents was obtained from a 4- week old DHBV positive duck infected with a standard DHBV 16 stock. F or wildtype DHBV, successful infection was determined by  
30 immunofluorescence staining of intracellular viral antigens with polyclonal rabbit antisera to DHBV proteins (D084 recognizing the preS-domain of DHBV L-protein or D087 recognizing denatured DHBV core protein) and a DTAF-labeled secondary goat-anti-rabbit antibody. In addition, cell culture medium was checked for progeny virus by DNA dot-blot analysis as described above.

35 After infection with the DHBV-GFP plasmids, cultured cells were monitored daily for green fluorescence by fluorescence microscopy using a standard FITC-filter set with excitation by blue light (488 nm). GFP expression was also checked by Western blot analysis. At the time of strongly positive green fluorescence, 10<sup>6</sup> primary

546993-033666

hepatocytes were lysed in 250µl protein-sample buffer (200 mM Tris-HCl pH 8.8, 10% glucose, 5 mM EDTA, 0.1% bromophenol blue, 3% SDS, 2% , β-mercaptoethanol). In addition, proteins from lysates of 10<sup>7</sup> transfected LMH cells (in 10 mM HEPES pH 7.5, 100 mM NaCl, 1 mM EDTA, 1% NP40) were immunoprecipitated using polyclonal  
5 rabbit anti-preS (D087) or anti-GFP (Clontech, Palo Alto, Ca., USA) antibodies and protein A sepharose. After washing, the pellet was dissolved in 50 µl protein-sample buffer. 25 µl of each lysate were separated by 10% SDS-PAGE, blotted to a PVDF membrane, immunostained with polyclonal antisera D084, D087 or D188 to DHBV proteins (D188 recognizing DHBV S-protein) or with polyclonal rabbit-anti-GFP  
10 antibody and visualized using the ECL-system (Amersham, Cleveland, Ohio, USA ).

Infectivity of recombinant virions was tested by infecting primary duck hepatocytes with rDHBV-S-GFP at different moi's (multiplicity of infection, measured as DNA-containing enveloped DHBV particles / primary cell) of 2 to 250 for 16 to 24 hours. Three days post infection, a faint green fluorescence became detectable, which  
15 increased markedly until day 5 and reached a maximum at day 8 post infection. The proportion of fluorescent cells was dependent on the multiplicity of infection used (see Figure 4). High multiplicities of infection of equal to or greater than 200 resulted in up to 90% of GFP positive cells.

Stable expression of the foreign gene was observed as long as viable hepatocytes  
20 could be kept in culture, with some variation in the intensity of green fluorescence between hepatocytes. Synthesis of DHBV core protein by rDHBV could be proven, as expected, by immunofluorescence costaining of GFP positive hepatocytes as well as by Western blot analysis of hepatocyte lysates. GFP-specific antibodies revealed two closely spaced bands of approximately 30 kDa, probably representing GFP and a  
25 DHBV-S/GFP-fusion. An additional RNA, initiating from the preS promoter, might serve for the expression of a preS/GFP fusion protein. However, no larger products corresponding to such a fusion protein were detected.

The number of fluorescent cells was strictly dose-dependent. As the recombinant viruses are replication-deficient, the percentage of GFP-positive cells can  
30 be taken as a measure for the infectious titre of incoming particles. At a multiplicity of infection of less than 5, only single cells showed a green fluorescence. Increasing moi's of 20 to 200 resulted in 5-10% to up to >90% of GFP positive hepatocytes. The intensity of green fluorescence varied between neighboring primary hepatocytes. Western blots of the cell lysates using anti-GFP antibodies showed again two  
35 immunoreactive bands around 30 kDa as in the transfected cells. These data demonstrate the efficient transfer and DHBV S-promoter controlled expression of a transgene by a recombinant hepadnavirus.

To test whether hepadnaviral vectors selectively target hepatocytes, cell-type specificity was analyzed *in vitro*. Primary hepatocyte cultures prepared by collagenase perfusion and differential sedimentation are known to contain 3 to 20% non-parenchymal liver cells, mainly sinusoidal endothelial cells and Kupffer cells (Johnston, D.E. & Jasuja, R. (1994) *Hepatology* 20:435-444). These can be distinguished from hepatocytes by their receptor-mediated uptake of acetylated LDL and by their ability to phagocytose (Irving, M. et al. (1984) *Gastroenterology* 87:1233-1247; McCuskey, R.S. et al. (1984) *Infect. Immun.* 45:278-280). None of these non-parenchymal cells, which accounted for some 15% of the total cell population in the cultures used in these experiments, showed GFP expression even after infection with rDHBV-GFP at a multiplicity of infection of 250-500. Similarly, no GFP expression was detectable when primary mouse hepatocytes (prepared as described in Example 3) were incubated with high multiplicity of infection rDHBV-GFP. These data indicate that delivery of the transgene by rDHBV is both hepatocyte- and species-specific.

To prove that rDHBV is suitable for liver-directed *in vivo* gene transfer, ducklings were infected at the day post hatching with  $10^9$  rDHBV-GFP particles via intravenous injection. At day 7 post infection, fixed liver-tissue sections and isolated hepatocytes from these animals were analyzed by immunofluorescence microscopy. GFP-fluorescent hepatocytes were detectable in both specimens (1-GFP-positive cell per  $10^4$  to  $10^5$  hepatocytes) indicating successful *in vivo* gene transfer by rDHBV-GFP.

**Example 5: IFN Gene Transfer by Recombinant DHBV Interferes  
with the Establishment of DHBV Infection**

IFN- $\alpha$  treatment is the current therapy of choice for chronic hepatitis B and hepatitis C. A homologous type I interferon has recently been cloned from ducks and addition of the recombinant protein to cultured fetal duck hepatocytes was shown to inhibit DHBV replication (Schultz *et al.*, (1995) *Virology* 212:641-649). Therefore, duck IFN was chosen to test whether a potentially therapeutic gene could be delivered by a hepadnaviral vector, and whether the secretory protein was functional. Inclusion of the authentic duck IFN signal sequence would allow for IFN secretion, which then should exert similar effects on DHBV replication as the exogenously added cytokine.

Primary duck hepatocytes were co-infected with rDHBV-IFN, or rDHBV-GFP as a negative control, and with replication-competent, serum derived wildtype DHBV. As a positive control, IFN protein was added to wildtype DHBV infected hepatocytes at day 3 post infection at which time expression of IFN from rDHBV-IFN was expected to start. Progeny virus release into the cell culture medium, resulting from productive infection with wildtype DHBV, was monitored by DHBV-DNA dot blot analysis.

Untreated wildtype DHBV infected cells and cells co-infected with rDHBV-GFP produced equally high levels of progeny DHBV, as assessed by dot blot analysis (see Figure 5A). In contrast, approximately 20-fold less progeny DHBV (14- to 24-fold in different experiments) was released from cells coinfecting with rDHBV-IFN (Figure 5A).  
5 Similar reductions (16- to 25-fold) were obtained by treatment with recombinant IFN (Figure 5A). Likewise, a strong suppression in the level of intracellular DHBV core- and L-protein was detected by Western blot analysis of cell lysates prepared at day 7 post infection (Figure 5B). Figure 5C shows a quantitative evaluation of the time course of DHBV production (DHBV-DNA equivalents). These data demonstrate that a  
10 functional cytokine expressed after hepadnaviral gene-transfer interferes with establishment of an hepadnaviral infection *in vitro*.

#### **Example 6: Recombinant DHBV Superinfects DHBV-Infected Hepatocytes**

For gene-therapeutic use in the treatment of chronic viral hepatitis, recombinant  
15 hepadnaviruses must be able to superinfect a liver with an established viral infection. To show that even superinfection of hepatocytes with a homologous virus is possible, primary hepatocytes were used from productively DHBV-infected ducks which all stained positive for DHBV S-protein, indicating productive DHBV infection. Incubation with rDHBV-GFP at moi's ranging from 25 to 100 resulted in 1-4% of GFP-  
20 positive hepatocytes (see Figure 6). Although this transduction efficiency is approximately 20-fold lower than the one observed with hepatocyte cultures not pre-infected with DHBV, coexpression of GFP in S-protein positive cells proved that hepatocytes with an established wildtype DHBV infection were superinfected by rDHBV-GFP.

#### **Example 7: IFN Gene Transfer Suppresses an Established DHBV Infection**

To test whether hepadnaviral cytokine gene transfer was principally suited for gene-therapy for chronic hepatitis B, DHBV-positive hepatocytes were superinfected with rDHBV-IFN and monitored for the release of progeny DHBV as described above.  
30 As shown in Fig. 7, DHBV production was decreased, relative to untreated controls, in a dose-dependent fashion, between 1.7 (multiplicity of infection of 25) and 4.5-fold (multiplicity of infection of 75), comparable to the effect observed by treatment with the cytokine protein at a dose showing maximal effect (4.1-fold reduction). No change in DHBV progeny production was seen upon superinfection with rDHBV-GFP, indicating  
35 that inhibition was caused by the transduced IFN gene.

**Example 8. Production of Recombinant HBV**

As a basis for constructing recombinant hepatitis B virus genomes carrying the GFP gene, we used plasmid pCH-9/3091, which, upon transfection, give rise to the production of infectious HBV particles (Obert, S. et al. (1996) *EMBO J.* 15: 2565-2574) (Fig. 2). As with the construction of recombinant DHBV, care was taken to neither exceed the authentic genome size nor to affect cis-acting control elements (Ganem, D. (1996) in *Hepadnaviridae: The Viruses and Their Replication*, eds. Fields, B.N., Knipe, D.M., and Howley, P.M., Lippincott: Philadelphia, vol. 2: 2703-2737; Nassal, M. and Schaller, H. (1996) *J. Viral. Hepat.* 3:217-226); and Seeger, C. & Hu, J. (1997) *Trends in Microbiol.* 5: 447-450), and similarly to the findings of the DHBV experiment, only substitution of the small envelope (S) gene by foreign sequences (Fig. 2) turned out to be successful.

Plasmid pCH-S-GFP elicited strong GFP fluorescence 36 to 38 hours after transfection into appropriate hepatoma cells, demonstrating functional insertion of the foreign gene. Since S gene replacement destroys the surface protein and polymerase open reading frames, for generation of recombinant virus, the corresponding gene products were trans-complemented by cotransfection (Condreay, L.D. et al. (1990) *J. Virol.* 64:3249-3258; Schlicht, H.J. et al. (1989) *Cell* 56: 85-92) of encapsidation deficient helper construct pCH3142 (Schlicht, H.J. et al. (1989) *Cell* 56: 85-92, Bartenschlager, R. et al. (1990) *J. Virol.* 64: 5324-5332). This resulted in the production of enveloped recombinant HBV (rHBV) at titers between  $10^8$  and  $10^9$ /ml. Virus could be concentrated up to 50-fold without loss of infectivity by polyethyleneglycol precipitation.

**Example 9: Successful Gene Transfer into Human Hepatocytes by Recombinant HBV Vectors**

Infectivity of recombinant virus particles was demonstrated by incubating primary human hepatocytes with equal amounts of rHBV-GFP or wild-type HBV. One per  $10^2$  hepatocytes was found to be infected with either virus at day 6 post infection, utilizing specific immunofluorescence staining for HBV core protein as the assay for infected cells. It was assumed that infectivity of the recombinant virus is comparable to that of wild-type virus. One per  $10^4$  hepatocytes showed clearly detectable GFP fluorescence, reaching its maximum at day 12 post infection. Due to the high auto-fluorescence background of human liver cells, weakly green fluorescent cells could not unequivocally be identified. Because of this technical limitation in GFP detection, assays detecting HBV core proteins were preferred for measurements of transduction efficiency.

**Example 10. Hepadnaviral Gene Transfer by HBV is Species and Hepatocyte-Specific**

To test whether HBV vectors selectively target hepatocytes, we analyzed cell-type specificity *in vitro*. Incubation of duck hepatocytes with rHBV-GFP or of mouse  
5 hepatocytes with rHBV-GFP did not result in GFP expression. Combined with the data  
(Experiment 9) demonstrating that GFP is expressed in human hepatocytes infected with  
rHBV-GFP, these data indicate that delivery of the transgene by rHBV is species-  
specific. Combined with the data (Example 4) demonstrating that neither sinusoidal  
endothelial cells nor Kupffer cells expressed GFP, these data indicate that delivery of the  
10 transgene by hepadnaviral vectors is species and hepatocyte-specific.

**EQUIVALENTS**

Those skilled in the art will recognize, or be able to ascertain using no more than  
routine experimentation, many equivalents to the specific embodiments of the invention  
15 described herein. Such equivalents are intended to be encompassed by the following  
claims.



We claim:

1. A method for expressing a heterologous gene in hepatocytes comprising:  
providing replication defective hepadnavirus particles at a titre level competent  
5 to infect hepatocytes, wherein a region of the preS or S-gene of the hepadnavirus  
genome has been replaced with the heterologous gene such that expression of the  
heterologous gene is regulated by regulatory sequences of the preS or S-gene; and  
infecting hepatocytes with the hepadnavirus such that the heterologous gene is  
delivered into the hepatocytes and expressed in the hepatocytes.  
10
2. The method of claim 1, wherein the replication defective hepadnavirus  
particles are human hepatitis B virus particles.
3. The method of claim 1, wherein the heterologous gene is inserted into a  
15 region of the S-gene such that nucleotides encoding at least one amino acid of the S  
protein are fused in-frame to the 5' end of the heterologous gene.
4. The method of claim 1, wherein the heterologous gene replaces a region  
of the S-gene.  
20
5. The method of claim 1, wherein the heterologous gene is inserted after  
the authentic AUG of the S-gene, and the heterologous gene is inserted such that  
nucleotides encoding at least one amino acid of the S protein are fused in-frame to the 5'  
end of the heterologous gene.  
25
6. The method of claim 1, wherein the heterologous gene encodes a  
modulating agent.
7. The method of claim 6, wherein the modulating agent is a cytokine.  
30
8. The method of claim 7, wherein the cytokine is IFN $\alpha$ .
9. A method of treating a subject with a hepatic disorder comprising:  
providing replication defective hepadnavirus particles at a titre level competent  
35 to infect hepatocytes of the subject with the hepatic disorder, wherein a region of the  
preS or S-gene of the hepadnavirus genome has been replaced with a therapeutic gene  
such that expression of the therapeutic gene is regulated by regulatory sequences of the  
preS or S-gene; and

infecting hepatocytes of the subject with the hepadnavirus particles such that the therapeutic gene is delivered into the hepatocytes and expressed in the hepatocytes at a level sufficient to treat the hepatic disorder.

5           10.     The method of claim 9, wherein the hepatic disorder is hepatitis B.

          11.     The method of claim 9, wherein the hepatic disorder is hepatitis C

          12.     The method of claim 9, wherein the hepatic disorder is selected from the  
10   group consisting of hepatocellular carcinoma, cirrhosis, steatosis, hemochromatosis, and  
      inherited liver disorders.

          13.     The method of claim 9, wherein the replication defective hepadnavirus  
15   particle is the human hepatitis B virus.

          14.     The method of claim 9, wherein the heterologous gene is inserted into a  
      region of the S-gene such that nucleotides encoding at least one amino acid of the S  
      protein are fused in-frame to the 5' end of the heterologous gene.

20           15.     The method of claim 9, wherein the heterologous gene replaces a region  
      of the S-gene.

          16.     The method of claim 9, wherein the heterologous gene is inserted after  
      the authentic AUG of the S gene, and the heterologous gene is inserted such that  
25   nucleotides encoding at least one amino acid of the S protein are fused in-frame to the 5'  
      end of the heterologous gene.

          17.     The method of claim 9, wherein the therapeutic gene is a modulating  
30   agent.

          18.     The method of claim 17, wherein the modulating agent is a cytokine.

          19.     The method of claim 18, wherein the cytokine is IFN $\alpha$ .

35           20.     The method of claim 18, wherein the cytokine is selected from the group  
      consisting of IFN $\gamma$ , IFN $\beta$ , IL-18 and TNF $\alpha$ .

21. The method of claim 9, wherein the hepadnavirus construct is directly administered to the subject.

22. The method of claim 9, wherein the hepadnavirus construct and a helper construct are cotransfected *in vitro* and the infectious particles produced from the culture are administered to the subject.

~~23.~~ A method of treating a subject with a hepatitis infection comprising:  
providing replication defective hepadnavirus particles at a titre level competent to infect hepatocytes of the subject with hepatitis, wherein a region of the preS or S-gene of the hepadnavirus genome has been replaced with a gene encoding a cytokine such that expression of the gene encoding a cytokine is regulated by regulatory sequences of the preS or S-gene; and

infected hepatocytes of the subject with the hepadnavirus such that the gene encoding a cytokine is delivered to the hepatocytes and expressed in the hepatocytes at a level sufficient to treat the hepatitis.

24. The method of claim 23, wherein the cytokine is IFN $\alpha$ .

25. The method of claim 23, wherein the cytokine is selected from the group consisting of TNF $\alpha$ , IFN $\beta$ , IL-18 and IFN $\gamma$ .

26. The method of claim 23, wherein the replication defective hepadnavirus particle is the human hepatitis B virus.

27. The method of claim 23, wherein the heterologous gene is inserted into a region of the S-gene such that nucleotides encoding at least one amino acid of the S protein are fused in-frame to the 5' end of the heterologous gene.

28. The method of claim 23, wherein the heterologous gene replaces a region of the S-gene.

29. The method of claim 23, wherein the heterologous gene is inserted after the authentic AUG of the S-gene, and the heterologous gene is inserted such that nucleotides encoding at least one amino acid of the S protein are fused in-frame to the 5' end of the heterologous gene.

30. The method of claim 23, wherein the gene encoding a cytokine is a modulating agent.

31. The method of claim 23, wherein the hepadnavirus particle is directly administered to the subject.

32. The method of claim 23, wherein the hepatitis infection is hepatitis B and the cytokine is IFN $\alpha$ .

33. A replication defective hepadnavirus particle, wherein a region of the preS or S-gene of the hepadnavirus genome has been replaced with a therapeutic gene such that expression of the therapeutic gene is regulated by regulatory sequences of the preS or S-gene.

34. The replication defective hepadnavirus particle of claim 33, wherein therapeutic gene is a cytokine.

35. The replication defective hepadnavirus particle of claim 34, wherein the cytokine is IFN $\alpha$ .

36. The replication defective hepadnavirus particle of claim 34, wherein the cytokine is selected from the group consisting of TNF $\alpha$ , IFN $\beta$ , IL-18 and IFN $\gamma$ .

37. A pharmaceutical composition comprising the replication defective hepadnavirus particle of claim 33 and a pharmaceutically acceptable carrier.

38. A pharmaceutical composition comprising the replication defective hepadnavirus particle of claim 33 and a helper virus.

39. A method of producing therapeutic replication defective hepadnavirus particles at a titre level suitable for therapeutic use comprising:

co-transfecting hepatoma cell lines with:

- (i) replication defective hepadnavirus constructs, wherein a region of the S-gene of the hepadnavirus DNA has been replaced with a gene encoding a therapeutic gene such that expression of the gene encoding a cytokine is regulated by regulatory sequences of the preS or S-gene; and

- (ii) a helper construct;

culturing the hepatocytes until infectious viral particles are produced; and

recovering the infectious viral particles.

40. The method of claim 9, wherein the recombinant hepadnavirus particles administered to the subject are produced by a helper cell line.

40. The method of claim 9, wherein the recombinant hepadnavirus particles administered to the subject are produced by a helper cell line.

## Methods and Compositions for Expressing Heterologous Genes in Hepatocytes Using Hepadnaviral Vectors


5

## Abstract

Methods and compositions for efficient, hepatocyte-specific delivery and expression of heterologous genes, both *in-vitro* and *in-vivo*, using hepadnaviral vectors are provided. Methods for expressing a heterologous gene in hepatocytes are provided involving: providing replication defective hepadnavirus particles at a titre level competent to infect hepatocytes, wherein a region of the preS/S-gene of the hepadnavirus genome has been replaced with the heterologous gene such that expression of the heterologous gene is regulated by regulatory sequences of the preS/S-gene; and infecting hepatocytes with the hepadnavirus such that the heterologous gene is delivered into the hepatocytes and expressed in the hepatocytes. Methods for treating a subject with a hepatic disorder (e.g., hepatitis infection) are also provided. Replication defective hepadnavirus particles, and pharmaceutical compositions thereof, are also provided. Methods of producing therapeutic replication defective hepadnavirus particles at a titre level suitable for therapeutic use are also provided.


20

a) DHBV wildtype plasmid (pCD16)



b) DHBV recombinant plasmids

rDHBV-S-GFP (pCD16-S-GFP/-IFN)



rDHBV-core-GFP (pCD16-core-GFP/-IFN)



encapsulation deficient DHBV helper (pCD4)






FIGURE 1



**FIGURE 2**






**FIGURE 3**


## FIGURE 4

669693 04666660



**FIGURE 5**

## FIGURE 6



**FIGURE 7**

Year	1970	1971	1972	1973	1974	1975	1976	1977	1978	1979	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037	2038	2039	2040	2041	2042	2043	2044	2045	2046	2047	2048	2049	2050	2051	2052	2053	2054	2055	2056	2057	2058	2059	2060	2061	2062	2063	2064	2065	2066	2067	2068	2069	2070	2071	2072	2073	2074	2075	2076	2077	2078	2079	2080	2081	2082	2083	2084	2085	2086	2087	2088	2089	2090	2091	2092	2093	2094	2095	2096	2097	2098	2099	2100																																																		
Population	1000000	1050000	1100000	1150000	1200000	1250000	1300000	1350000	1400000	1450000	1500000	1550000	1600000	1650000	1700000	1750000	1800000	1850000	1900000	1950000	2000000	2050000	2100000	2150000	2200000	2250000	2300000	2350000	2400000	2450000	2500000	2550000	2600000	2650000	2700000	2750000	2800000	2850000	2900000	2950000	3000000	3050000	3100000	3150000	3200000	3250000	3300000	3350000	3400000	3450000	3500000	3550000	3600000	3650000	3700000	3750000	3800000	3850000	3900000	3950000	4000000	4050000	4100000	4150000	4200000	4250000	4300000	4350000	4400000	4450000	4500000	4550000	4600000	4650000	4700000	4750000	4800000	4850000	4900000	4950000	5000000	5050000	5100000	5150000	5200000	5250000	5300000	5350000	5400000	5450000	5500000	5550000	5600000	5650000	5700000	5750000	5800000	5850000	5900000	5950000	6000000	6050000	6100000	6150000	6200000	6250000	6300000	6350000	6400000	6450000	6500000	6550000	6600000	6650000	6700000	6750000	6800000	6850000	6900000	6950000	7000000	7050000	7100000	7150000	7200000	7250000	7300000	7350000	7400000	7450000	7500000	7550000	7600000	7650000	7700000	7750000	7800000	7850000	7900000	7950000	8000000	8050000	8100000	8150000	8200000	8250000	8300000	8350000	8400000	8450000	8500000	8550000	8600000	8650000	8700000	8750000	8800000	8850000	8900000	8950000	9000000	9050000	9100000	9150000	9200000	9250000	9300000	9350000	9400000	9450000	9500000	9550000	9600000	9650000	9700000	9750000	9800000	9850000	9900000	9950000	10000000

Attorney's  
Docket  
Number BBI-102CP

## Declaration, Petition and Power of Attorney for Patent Application

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

METHODS AND COMPOSITIONS FOR EXPRESSING HETEROLOGOUS GENES IN HEPATOCYTES USING HEPADNAVIRAL VECTORS  
the specification of which

(check one)

X is attached hereto.

— was filed on \_\_\_\_\_ as \_\_\_\_\_

Application Serial No. \_\_\_\_\_

and was amended on \_\_\_\_\_  
(if applicable)

I do not know and do not believe that the subject matter of this application was known or used by others in the United States or patented or described in a printed publication in any country before my invention thereof, or patented or described in a printed publication in any country or in public use or on sale in the United States more than one year prior to the date of this application, or first patented or caused to be patented or made the subject of an inventor's certificate by me or my legal representatives or assigns in a country foreign to the United States prior to the date of this application on an application filed more than twelve months (six months if this application is for a design) before the filing of this application; and I acknowledge my duty to disclose information of which I am aware which is material to the examination of this application, that no application for patent or inventor's certificate on the subject matter of this application has been filed by me or my representatives or assigns in any country foreign to the United States, except those identified below, and that I have reviewed and understand the contents of the specification, including the claims as amended by any amendment referred to herein.

I acknowledge the duty to disclose to the Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

## CLAIM OF BENEFIT OF EARLIER FOREIGN APPLICATION(S)

I hereby claim priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below, and have also identified below any foreign application(s) for patent or inventor's certificate filed by me on the same subject matter having a filing date before that of the application(s) from which priority is claimed.

Check one:

☒ no such applications have been filed.

☐ such applications have been filed as follows

EARLIEST FOREIGN APPLICATION(S), IF ANY, FILED WITHIN 12 MONTHS  
(6 MONTHS FOR DESIGN) PRIOR TO THIS U.S. APPLICATION

Country	Application Number	Date of Filing (month,day,year)	Priority Claimed Under 35 USC 119
			<input type="checkbox"/> Yes <input type="checkbox"/> No
			<input type="checkbox"/> Yes <input type="checkbox"/> No
			<input type="checkbox"/> Yes <input type="checkbox"/> No
			<input type="checkbox"/> Yes <input type="checkbox"/> No
			<input type="checkbox"/> Yes <input type="checkbox"/> No

ALL FOREIGN APPLICATION(S), IF ANY FILED MORE THAN 12 MONTHS  
(6 MONTHS FOR DESIGN) PRIOR TO THIS U.S. APPLICATION


CLAIM FOR BENEFIT OF U.S. PROVISIONAL APPLICATION(S)

I hereby claim the benefit under 35 U.S.C. §119(e) of any United States provisional application(s) listed below.

60/098,173  
(Application Serial No.)

August 26, 1998  
(Filing Date)

\_\_\_\_\_  
(Application Serial No.)

\_\_\_\_\_  
(Filing Date)

60/098,173



# CLAIM FOR BENEFIT OF EARLIER U.S./PCT APPLICATION(S)

I hereby claim the benefit under Title 35, United States Code, §120 of any earlier United States application(s) or PCT international application(s) designating the United States listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the earlier application(s) in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose to the Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date(s) of the earlier application(s) and the national or PCT international filing date of this application. As to subject matter of this application which is common to my earlier application(s), if any, described below, I do not know and do not believe that the same was known or used by others in the United States or patented or described in a printed publication in any country before my invention thereof, or patented or described in a printed publication in any country or in public use or on sale in the United States more than one year prior to the date(s) of said earlier application(s), or first patented or caused to be patented or made the subject of an inventor's certificate by me or my legal representatives or assigns in a country foreign to the United States prior to the date(s) of said earlier application(s) on an application filed more than twelve months (six months if this application is for a design) before the filing of said earlier application(s); and I acknowledge that no application for patent or inventor's certificate on said subject matter has been filed by me or my representatives or assigns in any country foreign to the United States except those identified herein.

\_\_\_\_\_  
(Application Serial No.)

\_\_\_\_\_  
(Filing Date)

\_\_\_\_\_  
(Status)  
(patented,pending,aband.)

\_\_\_\_\_  
(Application Serial No.)

\_\_\_\_\_  
(Filing Date)

\_\_\_\_\_  
(Status)  
(patented,pending,aband.)

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorneys and/or agents to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

W. Hugo Liepmann	Reg. No. 20,407	Catherine J. Kara	Reg. No. 41,106
James E. Cockfield	Reg. No. 19,162	Faustino A. Lichauco	Reg. No. 41,942
Thomas V. Smurzynski	Reg. No. 24,798	Jeanne M. DiGiorgio	Reg. No. 41,710
Ralph A. Loren	Reg. No. 29,325	Megan E. Williams	Reg. No. 43,270
Giulio A. DeConti, Jr.	Reg. No. 31,503	Nicholas P. Triano III	Reg. No. 36,397
Ann Lamport Hammitte	Reg. No. 34,858	Peter C. Lauro	Reg. No. 32,360
Elizabeth A. Hanley	Reg. No. 33,505	Reza Mollaaghababa	Reg. No. 43,810
Amy E. Mandragouras	Reg. No. 36,207	Timothy J. Douros	Reg. No. 41,716
John V. Bianco	Reg. No. 36,748	John L. Welch	Reg. No. 28,129
Anthony A. Laurentano	Reg. No. 38,220	DeAnn F. Smith	Reg. No. 36,683
Jane E. Remillard	Reg. No. 38,872	William D. DeVaul	Reg. No. 42,483
Jeremiah Lynch	Reg. No. 17,425	David J. Ridders	Reg. No. 43,882
Kevin J. Canning	Reg. No. 35,470		
David A. Lane, Jr.	Reg. No. 39,261		

Send Correspondence to Elizabeth A. Hanley, Esq. at **Customer Number: 000959** whose address is:

Lahive & Cockfield, LLP, 28 State Street, Boston, MA 02109

Direct Telephone Calls to: (name and telephone number)

Elizabeth A. Hanley, Esq., (617) 227-7400

Wherefore I petition that letters patent be granted to me for the invention or discovery described and claimed in the attached specification and claims, and hereby subscribe my name to said specification and claims and to the foregoing declaration, power of attorney, and this petition.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor Heinz Schaller	
Inventor's signature	Date
Residence Jahnstrasse 21, 69120 Heidelberg, Germany	
Citizenship German	
Post Office Address (if different)	

Full name of second inventor, if any

Ulrike Protzer

Inventor's signature

---

Date \_\_\_\_\_

Residence

Im Linsenbuehl 13, 69221 Dossenheim, Germany

## Citizenship

German

Post Office Address (if different)

---

Full name of third inventor, if any

Michael Nassal

Inventor's signature

Date \_\_\_\_\_

Residence

Allensteiner Weg 3, 69181 Leimen, Germany

## Citizenship

German

---

Post Office Address (if different)